Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer

Hyunsoo Kim, Gun Yoon, Ji Yoon Ryu, Young Jae Cho, Jung Joo Choi, Yoo Young Lee, Tae Joong Kim, Chel Hun Choi, Sang Yong Song, Byoung Gie Kim, Duk Soo Bae, Jeong Won Lee

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Sphingosine kinase 1 (SPHK1), an oncogenic kinase, has previously been found to be upregulated in various types of human malignancy and to play a crucial role in tumor development and progression. Although SPHK1 has gained increasing prominence as an important enzyme in cancer biology, its potential as a predictive biomarker and a therapeutic target in cervical cancer remains unknown. SPHK1 expression was examined in 287 formalin-fixed, paraffin-embedded cervical cancer tissues using immunohistochemistry, and its clinical implications and prognostic significance were analyzed. Cervical cancer cell lines including HeLa and SiHa were treated with the SPHK inhibitors SKI-II or FTY720, and effects on cell survival, apoptosis, angiogenesis, and invasion were examined. Moreover, the effects of FTY720 on tumor growth were evaluated using a patient-derived xenograft (PDX) model of cervical cancer. Immunohistochemical analysis revealed that expression of SPHK1 was significantly increased in cervical cancer compared with normal tissues. SPHK1 expression was significantly associated with tumor size, invasion depth, FIGO stage, lymph node metastasis, and lymphovascular invasion. Patients with high SPHK1 expression had lower overall survival and recurrence-free survival rates than those with low expression. Treatment with SPHK inhibitors significantly reduced viability and increased apoptosis in cervical cancer cells. Furthermore, FTY720 significantly decreased in vivo tumor weight in the PDX model of cervical cancer. We provide the first convincing evidence that SPHK1 is involved in tumor development and progression of cervical cancer. Our data suggest that SPHK1 might be a potential prognostic marker and therapeutic target for the treatment of cervical cancer.

Original languageEnglish
Pages (from-to)26746-26756
Number of pages11
JournalOncotarget
Volume6
Issue number29
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Uterine Cervical Neoplasms
Neoplasms
Therapeutics
Heterografts
Apoptosis
sphingosine kinase
Tumor Burden
Paraffin
Formaldehyde
Cell Survival
Phosphotransferases
Survival Rate
Biomarkers
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Recurrence
Cell Line
Survival
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Hyunsoo ; Yoon, Gun ; Ryu, Ji Yoon ; Cho, Young Jae ; Choi, Jung Joo ; Lee, Yoo Young ; Kim, Tae Joong ; Choi, Chel Hun ; Song, Sang Yong ; Kim, Byoung Gie ; Bae, Duk Soo ; Lee, Jeong Won. / Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. In: Oncotarget. 2015 ; Vol. 6, No. 29. pp. 26746-26756.
@article{a8ae2e4a636e4093b3e1d8ee8b3d066c,
title = "Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer",
abstract = "Sphingosine kinase 1 (SPHK1), an oncogenic kinase, has previously been found to be upregulated in various types of human malignancy and to play a crucial role in tumor development and progression. Although SPHK1 has gained increasing prominence as an important enzyme in cancer biology, its potential as a predictive biomarker and a therapeutic target in cervical cancer remains unknown. SPHK1 expression was examined in 287 formalin-fixed, paraffin-embedded cervical cancer tissues using immunohistochemistry, and its clinical implications and prognostic significance were analyzed. Cervical cancer cell lines including HeLa and SiHa were treated with the SPHK inhibitors SKI-II or FTY720, and effects on cell survival, apoptosis, angiogenesis, and invasion were examined. Moreover, the effects of FTY720 on tumor growth were evaluated using a patient-derived xenograft (PDX) model of cervical cancer. Immunohistochemical analysis revealed that expression of SPHK1 was significantly increased in cervical cancer compared with normal tissues. SPHK1 expression was significantly associated with tumor size, invasion depth, FIGO stage, lymph node metastasis, and lymphovascular invasion. Patients with high SPHK1 expression had lower overall survival and recurrence-free survival rates than those with low expression. Treatment with SPHK inhibitors significantly reduced viability and increased apoptosis in cervical cancer cells. Furthermore, FTY720 significantly decreased in vivo tumor weight in the PDX model of cervical cancer. We provide the first convincing evidence that SPHK1 is involved in tumor development and progression of cervical cancer. Our data suggest that SPHK1 might be a potential prognostic marker and therapeutic target for the treatment of cervical cancer.",
author = "Hyunsoo Kim and Gun Yoon and Ryu, {Ji Yoon} and Cho, {Young Jae} and Choi, {Jung Joo} and Lee, {Yoo Young} and Kim, {Tae Joong} and Choi, {Chel Hun} and Song, {Sang Yong} and Kim, {Byoung Gie} and Bae, {Duk Soo} and Lee, {Jeong Won}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.4818",
language = "English",
volume = "6",
pages = "26746--26756",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

Kim, H, Yoon, G, Ryu, JY, Cho, YJ, Choi, JJ, Lee, YY, Kim, TJ, Choi, CH, Song, SY, Kim, BG, Bae, DS & Lee, JW 2015, 'Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer', Oncotarget, vol. 6, no. 29, pp. 26746-26756. https://doi.org/10.18632/oncotarget.4818

Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. / Kim, Hyunsoo; Yoon, Gun; Ryu, Ji Yoon; Cho, Young Jae; Choi, Jung Joo; Lee, Yoo Young; Kim, Tae Joong; Choi, Chel Hun; Song, Sang Yong; Kim, Byoung Gie; Bae, Duk Soo; Lee, Jeong Won.

In: Oncotarget, Vol. 6, No. 29, 01.01.2015, p. 26746-26756.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer

AU - Kim, Hyunsoo

AU - Yoon, Gun

AU - Ryu, Ji Yoon

AU - Cho, Young Jae

AU - Choi, Jung Joo

AU - Lee, Yoo Young

AU - Kim, Tae Joong

AU - Choi, Chel Hun

AU - Song, Sang Yong

AU - Kim, Byoung Gie

AU - Bae, Duk Soo

AU - Lee, Jeong Won

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Sphingosine kinase 1 (SPHK1), an oncogenic kinase, has previously been found to be upregulated in various types of human malignancy and to play a crucial role in tumor development and progression. Although SPHK1 has gained increasing prominence as an important enzyme in cancer biology, its potential as a predictive biomarker and a therapeutic target in cervical cancer remains unknown. SPHK1 expression was examined in 287 formalin-fixed, paraffin-embedded cervical cancer tissues using immunohistochemistry, and its clinical implications and prognostic significance were analyzed. Cervical cancer cell lines including HeLa and SiHa were treated with the SPHK inhibitors SKI-II or FTY720, and effects on cell survival, apoptosis, angiogenesis, and invasion were examined. Moreover, the effects of FTY720 on tumor growth were evaluated using a patient-derived xenograft (PDX) model of cervical cancer. Immunohistochemical analysis revealed that expression of SPHK1 was significantly increased in cervical cancer compared with normal tissues. SPHK1 expression was significantly associated with tumor size, invasion depth, FIGO stage, lymph node metastasis, and lymphovascular invasion. Patients with high SPHK1 expression had lower overall survival and recurrence-free survival rates than those with low expression. Treatment with SPHK inhibitors significantly reduced viability and increased apoptosis in cervical cancer cells. Furthermore, FTY720 significantly decreased in vivo tumor weight in the PDX model of cervical cancer. We provide the first convincing evidence that SPHK1 is involved in tumor development and progression of cervical cancer. Our data suggest that SPHK1 might be a potential prognostic marker and therapeutic target for the treatment of cervical cancer.

AB - Sphingosine kinase 1 (SPHK1), an oncogenic kinase, has previously been found to be upregulated in various types of human malignancy and to play a crucial role in tumor development and progression. Although SPHK1 has gained increasing prominence as an important enzyme in cancer biology, its potential as a predictive biomarker and a therapeutic target in cervical cancer remains unknown. SPHK1 expression was examined in 287 formalin-fixed, paraffin-embedded cervical cancer tissues using immunohistochemistry, and its clinical implications and prognostic significance were analyzed. Cervical cancer cell lines including HeLa and SiHa were treated with the SPHK inhibitors SKI-II or FTY720, and effects on cell survival, apoptosis, angiogenesis, and invasion were examined. Moreover, the effects of FTY720 on tumor growth were evaluated using a patient-derived xenograft (PDX) model of cervical cancer. Immunohistochemical analysis revealed that expression of SPHK1 was significantly increased in cervical cancer compared with normal tissues. SPHK1 expression was significantly associated with tumor size, invasion depth, FIGO stage, lymph node metastasis, and lymphovascular invasion. Patients with high SPHK1 expression had lower overall survival and recurrence-free survival rates than those with low expression. Treatment with SPHK inhibitors significantly reduced viability and increased apoptosis in cervical cancer cells. Furthermore, FTY720 significantly decreased in vivo tumor weight in the PDX model of cervical cancer. We provide the first convincing evidence that SPHK1 is involved in tumor development and progression of cervical cancer. Our data suggest that SPHK1 might be a potential prognostic marker and therapeutic target for the treatment of cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=84944463608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944463608&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4818

DO - 10.18632/oncotarget.4818

M3 - Article

VL - 6

SP - 26746

EP - 26756

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -